RE: RNS out11 May 2018 08:16
Early analysis of certain biomarker indicators suggest that the treatment did not produce the expected interferon-beta bioactivity in the treatment group that was previously seen in Faron's Phase I/II trial for Traumakine.
It is still too early to understand why this is the case and there are a number of possible causes that the Company are investigating including, inter alia, formulation, administration and deactivation. Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis.
Faron will provide an update with further information in due course.